Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Clinical Cancer Research 14, 4989-4994, August 1, 2008. doi: 10.1158/1078-0432.CCR-08-0389
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Wasielewski, M.
Right arrow Articles by Schutte, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wasielewski, M.
Right arrow Articles by Schutte, M.
Related Collections
Right arrow Epidemiology
Right arrow Epidemiology: Molecular Epidemiology

Cancer Prevention and Susceptibility

CHEK2 1100delC Is a Susceptibility Allele for HNPCC-Related Colorectal Cancer

Marijke Wasielewski1, Hans Vasen3, Juul Wijnen4, Maartje Hooning1, Dennis Dooijes2, Carli Tops4, Jan G.M. Klijn1, Hanne Meijers-Heijboer1,2 and Mieke Schutte1

Authors' Affiliations: Departments of 1 Medical Oncology and 2 Clinical Genetics, Josephine Nefkens Institute, Erasmus University Medical Center, Rotterdam, the Netherlands; 3 Department of Gastroentrology and 4 Center for Human and Clinical Genetics, Leiden University Medical Center, Leiden, the Netherlands

Requests for reprints: Mieke Schutte, Department of Medical Oncology, Josephine Nefkens Institute Room Be414, Erasmus University Medical Center, PO Box 2040, 3000 CA Rotterdam, the Netherlands. Phone: 31-10-7038039; Fax: 31-10-7044377; E-mail: a.schutte{at}erasmusmc.nl.

Purpose: The pathogenic CHEK2 1100delC variant is firmly established as a breast cancer susceptibility allele. Dutch CHEK2 1100delC breast cancer families frequently also include colorectal cancer cases, and the variant is particularly prevalent among breast cancer families with hereditary breast and colorectal cancer. Yet, it is still unclear whether CHEK2 1100delC also confers a colorectal cancer risk independent of its breast cancer risk.

Experimental Design: CHEK2 1100delC was genotyped in the index cases of 369 Dutch colorectal cancer families that had been excluded for familial breast cancer. The cohort included 132 cases with familial adenomatous polyposis (FAP) and FAP-related disease, and 237 cases with hereditary nonpolyposis colorectal cancer (HNPCC) and HNPCC-related disease.

Results: None of the FAP/FAP-related cases carried the CHEK2 1100delC variant. In contrast, CHEK2 1100delC was present in 10 of 237 (4.2%) HNPCC/HNPCC-related cases that was significantly more prevalent than the 1.0% Dutch population frequency (odds ratio, 4.3; 95% confidence interval, 1.7-10.7; P = 0.002). Nine of the 10 CHEK2 1100delC colorectal cancer cases met the revised Amsterdam and/or Bethesda criteria. The 10 CHEK2 1100delC colorectal cancer families had a high-risk cancer inheritance pattern, including 35 colorectal cancer cases, 9 cases with polyps, and 21 cases with other tumor types.

Conclusion: Our analysis provides strong evidence that the 1100delC variant of CHEK2 confers a colorectal cancer risk in HNPCC/HNPCC-related families, supporting the hypothesis that CHEK2 is a multiorgan cancer susceptibility gene.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.